NCT06337617已完成不适用
A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Real-world overall response rate (rwORR)
研究概览
简要总结
This was a multi-center, observational, retrospective cohort study to evaluate the effectiveness and safety of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic BRAF V600 mutation positive melanoma, for mucosal melanoma patients (Cohort A) and non-mucosal melanoma patients (Cohort B, cutaneous and acral melanoma), separately. Study population was identified as patients initiating dabrafenib plus trametinib from 01 May 2020 to 31 July 2022 who fulfilled the inclusion/exclusion criteria. The follow-up period ended at the earliest of the following: end of study observation period (i.e., 31 December 2022), death, upon withdrawal of consent or the last available record.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cohorts A and B:
- •Initiated dabrafenib and trametinib combination therapy (D+T) according to approved label between 01 May 2020 and 31 July 2022
- •Was ≥18 years old of age at the initiation of D+T
- •Had at least one tumor assessment after initiation of D+T
- •Written informed consent if requested by the study site
- •Cohort A Only • Confirmed BRAF V600 mutation positive mucosal melanoma that was unresectable or metastatic
- •Cohort B Only
- •Confirmed BRAF V600 mutation positive non-mucosal melanoma (cutaneous and acral melanoma) that was unresectable or metastatic
排除标准
- •None specified
结局指标
主要结局
Real-world overall response rate (rwORR)
时间窗: Up to approximately 2.6 years
ORR was defined as the percentage of patients demonstrating a best overall response as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or as documented per physician assessment, as available.
次要结局
- Number and percentage of patients per anatomic sites of origin(Baseline)
- Number and percentage of patients per tumor stage(Baseline)
- Number and percentage of patients per metastatic location(Baseline)
- Mean Age(Baseline)
- Lactate dehydrogenase (LDH) levels(Baseline)
- Number and percentage of patients per surgical and medical procedure(Baseline)
- Number and percentage of patients with prior anti-neoplastic drugs for melanoma per treatment intent(Baseline)
- Percentage of patients per sex(Baseline)
- Number of years of disease history at treatment initiation since initial melanoma diagnosis(Baseline)
- Number of years of disease history at treatment initiation since unresectable or metastatic melanoma diagnosis(Baseline)
- Number and percentage of patients with occurrence of tumor metastasis(Baseline)
- Number and percentage of patients per type of surgery(Baseline)
- Number and percentage of patients who had at least one radiotherapy for melanoma prior to D+T treatment(Baseline)
- Number and percentage of patients per radiation site(Baseline)
- Number and percentage of patients with prior radiotherapy for melanoma with best overall tumor response(Baseline)
- Number and percentage of patients with dabrafenib plus trametinib treatment per line of treatment(Up to approximately 2.2 years)
- Number and percentage of patients with dabrafenib plus trametinib treatment per treatment intent(Up to approximately 2.2 years)
- Number and percentage of patients with dabrafenib plus trametinib treatment per treatment setting(Up to approximately 2.2 years)
- rwPFS for dabrafenib plus trametinib (NMS), by immunotherapy use(Up to approximately 2.6 years)
- Number and percentage of patients with systemic anti-neoplastic treatment after D+T(Up to approximately 2.6 years)
- Number and percentage of patients with prior radiotherapy for melanoma per treatment intent(Baseline)
- Number and percentage of patients with prior radiotherapy for melanoma per treatment setting(Baseline)
- Number and percentage of patients per metastases(Baseline)
- Eastern Cooperative Oncology Group (ECOG) performance status(Baseline)
- Mean duration of D+T, if not ongoing to end of study follow-up(Up to approximately 2.2 years)
- Real-world progression-free survival (rwPFS) for dabrafenib plus trametinib (FAS)(Up to approximately 2.6 years)
- Real-world overall survival (rwOS) since D+T initiation (FAS)(Up to approximately 2.6 years)
- Number and percentage of patients with serious adverse events (SAEs) (FAS)(Up to approximately 2.6 years)
- rwOS since D+T initiation (MMS), by immunotherapy use(Up to approximately 2.6 years)
- Real-world overall survival since the first anti-neoplastic drug treatment for advanced/metastatic melanoma (FAS)(Up to approximately 2.6 years)
- Number and percentage of patients who had at least one surgery for melanoma prior to D+T treatment(Baseline)
- Number and percentage of patients per name of surgery(Baseline)
- Number and percentage of patients who had at least one anti-neoplastic drug for melanoma prior to D+T treatment(Baseline)
- Number and percentage of patients with prior anti-neoplastic drug for melanoma per line of treatment(Baseline)
- Number and percentage of patients with prior anti-neoplastic drug for melanoma per treatment type(Baseline)
- Number and percentage of patients with prior anti-neoplastic drug for melanoma with best overall tumor response(Baseline)
- Number and percentage of patients per prior anti-neoplastic drug for melanoma(Baseline)
- Number and percentage of patients per type of D+T treatment change(Up to approximately 2.2 years)
- Number and percentage of patients per reason for D+T treatment change(Up to approximately 2.2 years)
- Number and percentage of patients with prior anti-neoplastic drug for melanoma per treatment setting(Baseline)
- Number and percentage of patients per reason for immunotherapy discontinuation(Up to approximately 2.6 years)
- rwORR of dabrafenib plus trametinib among non-mucosal melanoma patients (FAS)(Up to approximately 2.6 years)
- Real-world disease control rate (rwDCR) of D+T (FAS)(Up to approximately 2.6 years)
- Mean total dosage for all radiotherapy(Baseline)
- Real-world duration of response (rwDOR) of dabrafenib plus trametinib(Up to approximately 2.6 years)
- Time to treatment discontinuation (FAS)(Up to approximately 2.6 years)
- rwPFS for dabrafenib plus trametinib (MMS), by immunotherapy use(Up to approximately 2.6 years)
- Number and percentage of patients who had systemic anti-neoplastic treatment after D+T treatment per medication(Up to approximately 2.6 years)
- Number and percentage of patients per concomitant medication(Up to approximately 2.2 years)
- Number and percentage of patients with adverse events of special interest (AESIs) (FAS)(Up to approximately 2.6 years)
- Number and percentage of patients with systemic anti-neoplastic treatment after D+T and treatment ongoing at end of follow up(Up to approximately 2.6 years)
- Number and percentage of patients with systemic anti-neoplastic treatment after D+T per treatment type(Up to approximately 2.6 years)
- Number and percentage of patients who had systemic anti-neoplastic treatment after D+T treatment(Up to approximately 2.6 years)
- Real-world overall survival since the first anti-neoplastic drug for advanced/metastatic melanoma (NMS), by immunotherapy use(Up to approximately 2.6 years)
- rwOS since D+T initiation (NMS), by immunotherapy use(Up to approximately 2.6 years)
- Number and percentage of patients with systemic anti-neoplastic treatment after D+T with best overall tumor response(Up to approximately 2.6 years)
- Number and percentage of patients with systemic anti-neoplastic treatment after D+T per line of treatment(Up to approximately 2.6 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo TransferInfertility, FemaleNCT05130125LG Chem1,166
已完成
不适用
Retrospective study focusing on efficacy and safety of Omidenepag isopropylGlaucoma or Ocular hypertensionJPRN-UMIN000040040Santen Pharmaceutical Co. Ltd.827
已完成
不适用
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 InfectionHIV InfectionsNCT01902615Hoffmann-La Roche58
已完成
不适用
Post Market, Retrospective Study to Evaluate Patients Implanted With Medacta Versafit Cup DM ™️ 2 Years Post-opHip ArthritisNCT03897387Medacta USA316
已完成
不适用
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML PatientsChronic Myeloid LeukemiaNCT05619978Novartis Pharmaceuticals200